Smoked cannabis as an adjunctive second-line therapy to treat chronic peripheral neuropathy can be both effective and cost-effective, suggests a new study that used a computer simulation model to simulate its use in one million patients.

See the source article by following the link below:
Smoked cannabis as an adjunctive second-line therapy to treat chronic peripheral neuropathy can be both effective and cost-effective, suggests a new study that used a computer simulation model to simulate its use in one million patients.